Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Travatan

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Objective: To assess symptoms of ocular surface disease (OSD) in patients treated with a BAK-preserved Xalatan (Latanoprost) to… Expand
  • table 1
  • table 2
  • table 3
2011
2011
PURPOSE To determine the element that modulates benzalkonium chloride (BAC) toxicity by using a new electrophysiological method… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
2011
2011
PURPOSE To evaluate the safety and efficacy of timolol 0.5%/travoprost 0.004% combination (duotrav) as observed in primary open… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
2010
2010
PURPOSE To quantify the aqueous humor (AH) concentrations of bimatoprost (amide), travoprost (isopropyl ester), and their… Expand
2010
2010
Purpose The toxicity of antiglaucoma medications to ocular surface cells has been evaluated extensively; however, the toxicity to… Expand
  • table 1
  • figure 1
  • figure 2
2010
2010
Purpose: This study evaluated the cytotoxicity of five prostaglandin analog ophthalmic solutions on four ocular surface cell… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • table 1
2007
2007
Travoprost Z (Travatan® Z) ophthalmic solution has recently been approved for the reduction of elevated intraocular pressure (IOP… Expand
2006
2006
The aim of investigation was to study the effect of travatan on intraocular pressure (IOP) in patients with primary open-angle… Expand